Cancer Risk from Pork Leads FDA to Withdraw Approval for Drug Used to Treat Pigs

Following concerns that humans may face a risk of cancer from residue in pork, federal regulators have withdrawn approval for the swine drug carbadox, which has been on the market since 1972. 

The FDA’s Center for Veterinary Medicine (CVM) announced that it was withdrawing approval for carbadox, a drug for pigs, after determining that cancerous residue could be left in certain pork products, especially pork liver, which is derived from animals treated with the drug. However, the agency is not suggesting people change their pork-eating habits.

According to the agency, it recently reexamined the safety profile of carbadox, which is manufactured by Phibro Animal Health, based in Teaneck, New Jersey, and is used to prevent dysentery and bacterial enteritis in pigs. It is also often used to help pigs gain weight.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

“The manufacturer of carbadox has failed to provide sufficient data to demonstrate the safety of this drug given evidence that carbadox may result in carcinogenic residues,” Michael R. Taylor, FDA deputy commissioner of food and veterinary medicine, said in the press release. “As a result, FDA’s Center for Veterinary Medicine is taking legal action to remove this product from the marketplace.”

The move concludes a safety review initiated by the agency after a July 2014 study conducted by the United Nations and World Health Organization committee, which determined that there were no safe levels of residue of carbadox (PDF) that constituted an acceptable risk to consumers. The FDA says it sees a potential risk to human health, particularly in products made from pork liver, like hot dogs, liverwurst, and some lunch meat and sausages.

The FDA says that eating pork from pigs given carbadox is not likely to affect a person’s lifetime risk of cancer significantly, but that removing it from the market will lower the overall lifetime risk to consumers.

The agency notes that there are other FDA-approved antibiotics available to treat swine and that the CVM will work with pork producers to minimize the impacts on the industry.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A panel of federal judges will decide in December whether to consolidate all claims brought by parents who allege that Roblox facilitated child sexual exploitation into a multidistrict litigation.
A federal judge has called for a second census of Suboxone tooth decay lawsuits and will require prompt filing of census forms for claims filed from October 1 forward.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.